Skip to content

Is FDA Approval for Renal Denervation on the Horizon?


On August 22-23, 2023, the FDA will conduct an Advisory Committee Meeting to discuss, make recommendations, and vote on renal denervation devices (e.g., devices indicated to reduce blood pressure in patients with hypertension).  On August 22, the Advisory Committee will discuss the Paradise Ultrasound Renal Denervation System by ReCor Medical, a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd.  The following day, the Advisory Committee will discuss the Symplicity Spyral Renal Denervation System by Medtronic, Inc..  According to the FDA’s meeting announcement, such advisory committees “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.”

The FDA’s meeting will be conducted virtually and will be open to the public.  The FDA intends to make background material available to the public at least two business days before the meeting.  Background material and the link to the online teleconference meeting room will be posted to the FDA’s website.

This meeting comes on the heels of a recent recommendation made by the European Society of Hypertension (ESH) during its 32nd annual scientific meeting in late June.  Specifically, the ESH recommended that, under certain conditions, renal denervation be offered as an additional therapy to patients with hypertension.  The ESH recommendation comes after a similar recommendation from the European Society of Cardiology earlier this year.

Medtronic issued a press release shortly after the ESH recommendation.  Jason Weidman, Senior Vice President and President of the Coronary and Renal Denervation business at Medtronic, remarked:

“This is a positive step forward for the Symplicity Blood Pressure Procedure and underscores the desire of the clinical community to include new treatment options to improve hypertension control rates.”

Several other companies are also seeking FDA approval for renal denervation systems.  For example, Sonivie received investigational device exemption (IDE) approval for its Therapeutic Intra-Vascular Ultrasound (TIVUS) System in 2022 and Metavention announced on June 21, 2023 that it received IDE approval to initiate a pivotal study on its integrated radiofrequency renal denervation system.


, , , , , , , ,

Is FDA Approval for Renal Denervation on the Horizon? Headshot

Michael Christensen

Michael R. Christensen is a partner in our Orange County office. Mr. Christensen represents clients in the medical device, electronics, media and entertainment, and computer software fields. While he has helped clients protect a variety of technologies, Mr. Christensen focuses on building patent portfolios for medical device clients in the neurovascular, neuromodulation and spine fields.

Mr. Christensen also has extensive experience conducting patent due diligence for leading Venture Capital firms and other investors. He has also performed several IP audits to help companies identify ways to improve their patent portfolio. One of Mr. Christensen’s areas of expertise is developing strategies for expediting patent prosecution both in the United States and abroad. Prior to joining the firm, Mr. Christensen clerked with firms in Seattle, Salt Lake City and Irvine. While pursuing his undergraduate degree in electrical engineering, Mr. Christensen served as a Teaching Assistant in a semiconductor device fabrication lab in addition to taking courses focusing on digital system design and digital communication theory.

Mr. Christensen was a summer associate with the firm in 2007 and he joined the firm as an associate in 2008.

View all posts published by Michael Christensen
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal